Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model

References

• Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;10:32
   PubMed Web of Science ®Google Scholar
• Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121–8
   PubMed Web of Science ®Google Scholar
• McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235–6
   PubMed Web of Science ®Google Scholar
• Pietrowski D, Szabo L, Sator M, et al. Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 2012;27:196–9
   PubMed Web of Science ®Google Scholar
• Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751–5
   PubMed Web of Science ®Google Scholar
• Hård AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatr 2011;100:1523–7
   PubMed Web of Science ®Google Scholar
• Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 2010;89:692–9
   PubMed Web of Science ®Google Scholar
• Tong XM, Zhang SY, Song T, et al. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl) 2008;121:2434–9
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Ohba T, Tanaka N, et al. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. Endocr J 2003;50:515–25
   PubMed Web of Science ®Google Scholar
• Ricci AG, Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci 2011;18:614–22
   PubMed Web of Science ®Google Scholar
• Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010;28:448–57
   PubMed Web of Science ®Google Scholar
• Lindenbaum ES, Bar Sela P, Itzkovitz J, et al. Ovarian hyperstimulation in rats. Eur J Obstet Gynecol Reprod Biol 1980;11:57–67
   PubMed Web of Science ®Google Scholar
• Ujioka T, Matsuura K, Kawano T, Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod 1997;12:1629–34
   PubMed Web of Science ®Google Scholar
• Ujioka T, Matsuura K, Tanaka N, Okamura H. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. Hum Reprod 1998;13:3009–15
   PubMedGoogle Scholar
• Huddleston HG, Racowsky C, Jackson KV, et al. Coasting vs. cryopreservation of all embryos for prevention of OHSS in in vitro fertilization. Fertil Steril 2008;90:1259–62
   PubMed Web of Science ®Google Scholar
• Busso CE, Garcia-Velasco J, Gomez R, et al. Symposium: update on prediction and management of OHSS. Prevention of OHSS–dopamine agonists. Reprod Biomed Online 2009;19:43–51
   PubMed Web of Science ®Google Scholar
• Moraloglu O, Işik H, Kiliç S, et al. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertil Steril 2011;95:2638–41
   PubMed Web of Science ®Google Scholar
• Ignjatovic D, Aasland K, Pettersen M, et al. Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 2010;200:270–5
   PubMed Web of Science ®Google Scholar
• Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol 2012;24:8–13
   PubMed Web of Science ®Google Scholar
• Nomoto H, Shiraga F, Kuno N. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Opthalmol Vis Sci 2009;50:4807–13
   PubMed Web of Science ®Google Scholar